Last updated: July 5, 2026

THEOPHYL-SR market dynamics and financial trajectory: sales trends, payer dynamics, and generic risk

Executive summary: THEOPHYL-SR (theophylline, sustained-release) has a limited, niche branded market in the US, with revenue driven by long-term maintenance prescriptions for COPD/asthma-adjunct use rather than acute utilization. Competitive pressure is persistent because theophylline sustained-release products face broad generic availability and ongoing substitution. Financial trajectory typically tracks generic pricing compression and formulary tightening, with branded share shrinking as A-rated multisource products gain access through contracting and pharmacy benefit manager (PBM) preferences.

What is THEOPHYL-SR and how is it used clinically?

Direct answer: THEOPHYL-SR is a sustained-release theophylline product used as maintenance therapy in obstructive airway disease, historically for COPD and as an adjunct in asthma when other options are insufficient or contraindicated.

Dosing form and differentiation

Sustained-release (SR) oral theophylline is typically differentiated by release profile, tablet strength options, and excipient system.
In practice, these products are treated as therapeutically substitutable by many payers when bioequivalence is established.

Typical prescribing patterns

Chronic use supports repeat prescribing.
Utilization is sensitive to:
- guideline shifts that deprioritize xanthines,
- safety monitoring practices (narrow therapeutic index considerations),
- patient-specific tolerability and historical response.

How do market dynamics shape THEOPHYL-SR demand?

Direct answer: Demand is anchored in chronic maintenance prescribing but constrained by generic competition, payer formulary substitution, and guideline-driven preference changes.

Guideline and therapy mix pressure

Xanthines have long been under pressure versus inhaled corticosteroids, long-acting bronchodilators, and biologics where appropriate.
As COPD and asthma management evolves, xanthines tend to retain a role in:
- older lines of therapy,
- patients stabilized previously on theophylline,
- limited-option scenarios.

Payer and PBM substitution dynamics

Generic availability for theophylline SR drives:
- lower branded net price realization over time,
- higher formulary preference for contracted generic SKUs,
- pharmacist substitution at point of sale where permitted.
Formulary management often treats SR theophylline classes as “interchangeable” for coverage decisions when clinical monitoring is feasible.

Procurement and contracting effects

Many payers use tiered coverage:
- preferred tier for lowest-cost generic,
- restricted coverage for non-preferred branded unless clinically justified.
Contracting typically intensifies at the time of generic entry or when PBMs rebid formularies.

What is the financial trajectory of THEOPHYL-SR sales over time?

Direct answer: The financial trajectory for a branded sustained-release theophylline product is expected to show declining or flat-to-declining sales after sustained generic penetration, with modest stabilization only when:

the branded SKU retains a formulary position,
competitive generic set is limited in a specific strength/package combination,
supply continuity reduces substitution opportunities temporarily.

Revenue drivers and headwinds

Drivers

Chronic maintenance utilization base.
Patient persistence in stabilized cohorts.
Institutional retention if generics are less tolerated or monitoring burden increases with switching.

Headwinds

Generic price compression and rebates that shrink branded net revenue.
PBM formulary exclusion or down-tiering.
Clinical tendency to use alternative COPD/asthma controller regimens.

What patents protect THEOPHYL-SR, and how long does protection last?

Direct answer: Patent protection for legacy theophylline SR products in the US has largely expired in standard therapeutic and composition families; the remaining value is usually tied to later formulation, manufacturing, or specific dosage strength IP, if any.

Why the estate matters less in practice for this class

Theophylline as a molecule is long off the original novelty curve.
Competitive generic access is typically governed by:
- expiration of remaining formulation/manufacturing patents (if present),
- ANDA approval pathways and bioequivalence for SR release,
- any regulatory exclusivities tied to specific listed products (less common for this class).

What is the Orange Book status of THEOPHYL-SR?

Direct answer: The Orange Book status for THEOPHYL-SR is typically characterized by multisource availability with limited remaining exclusivity, consistent with the general market structure of older generic-dominant products.

What to expect in an Orange Book review

Multiple listed products with the same active ingredient (theophylline) and SR dosage form.
Potential presence of patents tied to specific strength presentations.
If patents are still listed, they are often late-stage formulation or method-of-manufacture claims rather than foundational therapeutic use.

What generic entry risks exist for THEOPHYL-SR?

Direct answer: Generic entry risk is low only when a given strength/package is temporarily sheltered; otherwise, the broader theophylline SR market is structurally exposed to continued generics and substitution.

Entry pathways and practical risk vectors

ANDA approvals rely on bioequivalence; SR products can be substituted when release profile meets BE standards.
Risk is driven by:
- the number of approved generic manufacturers by strength,
- PBM contracting favoring lowest-net-cost SKUs,
- discontinuations and reintroductions that can create short-lived supply gaps.

Which companies compete with THEOPHYL-SR in the US?

Direct answer: Competition comes primarily from generic theophylline sustained-release manufacturers and any branded remaining in the SR segment by strength.

Competitive landscape shape

Generic competition typically reduces:
- list price,
- net price (after rebates),
- branded share.
Differentiation is limited because the active ingredient is theophylline and the clinical use pattern is maintenance.

How does THEOPHYL-SR compare with other theophylline sustained-release products?

Direct answer: Versus other theophylline SR SKUs, THEOPHYL-SR competes mainly on:

net price after payer rebates and contracting,
coverage tier placement,
perceived stability of supply,
ability to avoid patient switching costs.

Switchability and patient monitoring

Theophylline has a narrow therapeutic index, so switching between SR products may require closer monitoring early after transition.
This can slow down substitution for some patients, but does not usually stop it over time once payer access improves for lower-cost alternatives.

When does THEOPHYL-SR lose exclusivity and what does that imply for pricing?

Direct answer: If any remaining formulation or manufacturing patents exist for THEOPHYL-SR, exclusivity loss would translate into step-down net pricing and immediate share transfer to contracted generics, with further downside from annual PBM rebate and bid cycles.

Pricing and share implication framework

Event-driven decline:
- patent expiry or generic entry often creates a near-term market share shift.
Structural decline:
- even without a discrete legal event, continued multi-source competition drives ongoing net price compression.

What FDA regulatory status and pathway issues affect THEOPHYL-SR?

Direct answer: THEOPHYL-SR is regulated as a conventional small-molecule drug product; its sustained-release performance is governed by formulation and manufacturing controls, not a biologic-like regulatory exclusivity regime.

What matters for commercial risk

SR bioequivalence for generics.
Manufacturing site approvals and inspection outcomes.
Label changes that affect dosing instructions, monitoring, or warnings.

What patent litigation affects THEOPHYL-SR?

Direct answer: Litigation is usually limited for older theophylline products because the active ingredient and core compositions are long unpatented; where disputes exist, they are typically around later formulation or process patents.

How litigation would show up commercially

A litigation stay or settlement can delay generic launches for specific ANDA filers by strength.
Absent such barriers, generics enter and compress net pricing quickly.

What settlement agreements or licensing deals govern generics for THEOPHYL-SR?

Direct answer: No settlement-specific dynamics can be stated without enumerating the relevant ANDA cases tied to THEOPHYL-SR-specific Orange Book patents and strengths.

How resilient is THEOPHYL-SR revenue in a generic-dominant market?

Direct answer: Resilience depends on payer tier placement and continuity of patient cohorts willing to stay on a branded SR product due to tolerability or monitoring patterns. In most mature generic classes, resilience is temporary and erodes with contracting.

Metrics that would typically define resilience

Branded to generic unit share by strength.
Net price trend by major channel:
- retail,
- mail,
- 340B or institutional.
Pharmacy benefit tiering:
- preferred coverage reduces switching friction for generics.
Persistence:
- medication possession ratio and refill cadence among maintenance users.

Revenue exposure: what percentage of branded revenue is at risk from formulary substitution?

Direct answer: For legacy branded theophylline SR products, most revenue is exposed to formulary substitution because branded value is price and coverage position rather than differentiated clinical benefit.

Mechanism of revenue risk

PBM contracts drive:
- down-tiering,
- exclusion,
- preferential dispensing of contracted generics.
As multi-source volume increases, plan reimbursement shifts toward lowest net cost.

Key takeaways

THEOPHYL-SR’s market is chronic, niche, and maintenance-driven, with demand constrained by guideline preference shifts away from xanthines.
Financial trajectory in branded sustained-release theophylline is dominated by generic competition, PBM contracting, and ongoing net price compression.
Patent exclusivity, if any remains, is likely limited to late-stage formulation or manufacturing IP; once that is cleared, share and pricing typically shift quickly toward contracted generics.
Revenue resilience is mainly a function of formulary positioning and patient switching friction tied to monitoring practices.

FAQs

Why do payers prefer generic sustained-release theophylline over THEOPHYL-SR?
Coverage decisions typically prioritize lowest net cost and accepted bioequivalence interchangeability for SR theophylline products.
Does theophylline’s narrow therapeutic index increase substitution risk for THEOPHYL-SR?
It can increase early monitoring needs after switching, but it rarely prevents long-term payer-driven substitution.
How do PBM rebates influence THEOPHYL-SR net revenue?
Branded net pricing depends on rebate and contracting terms; generic dominance usually forces higher rebates to retain tier placement.
What happens to branded theophylline SR sales after a new generic strength enters?
Sales typically shift toward the lowest net cost SKU within weeks to a few quarters as formularies and pharmacy dispensing habits adjust.
Are method-of-manufacturing or formulation patents the main remaining IP for THEOPHYL-SR?
In legacy drug classes like theophylline SR, any remaining IP is usually tied to later formulation/manufacturing improvements rather than core compositions.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (US). U.S. Food and Drug Administration.
FDA. ANDA Bioequivalence and related guidance documents. U.S. Food and Drug Administration.

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	142
Patent Applications:	3,330
DailyMed Link:	THEOPHYL-SR at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Pharm	THEOPHYL-SR	theophylline	CAPSULE, EXTENDED RELEASE;ORAL	086480-001	Feb 8, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ortho Mcneil Pharm	THEOPHYL-SR	theophylline	CAPSULE, EXTENDED RELEASE;ORAL	086471-001	Feb 8, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for THEOPHYL-SR